Tags: Drug.
Romosozumab (AMG 785) is a humanized monoclonal antibody that targets sclerostin for the treatment of osteoporosis.Romosozumab was originally discovered by Celltech (now owned by UCB). Celltech entered in a partnership with Amgen in 2002 for the product’s development.Romosozumab is of interest because of sclerostin’s specificity to bone. Its use has increased bone growth in preclinical trials in osteoporotic rats and monkeys.